“Celiac Disease Treatment: Current Options and Emerging Therapies”

The Foundation: Strict Gluten-Free Diet

Every person with celiac disease needs to understand one thing above all else: gluten elimination is not optional, not a preference, and not something that can be relaxed once symptoms improve. The gluten-free diet is a medical treatment. Continued gluten exposure, even in small amounts, perpetuates intestinal inflammation and villous atrophy regardless of whether symptoms are noticeable.

Gluten is the protein complex found in wheat (including spelt, kamut, farro, durum, and semolina), barley, and rye. Oats are technically gluten-free but are commonly contaminated during processing, and a subset of celiac patients react to the oat protein avenin even from uncontaminated sources. The threshold for harm in celiac disease is very low: as little as 10-50 mg of gluten per day can cause intestinal damage, and a single crouton contains roughly 500 mg [1].

Working with a dietitian experienced in celiac disease is strongly recommended at diagnosis. The learning curve for a strict gluten-free diet is steep, and hidden sources of gluten are numerous: soy sauce, salad dressings, medications, communion wafers, lipsticks, and many processed foods all carry contamination risk.

What to Expect During Recovery

Symptom improvement typically begins within days to weeks of starting a strict gluten-free diet. GI symptoms often resolve first. Fatigue, brain fog, and mood changes may take several months to improve as nutritional deficiencies are corrected. Serological markers (tTG-IgA) normalize over 6-12 months in most adults. Intestinal healing is slower: the majority of adults achieve mucosal recovery within 2 years, though a significant proportion show persistent villous atrophy at repeat biopsy even with apparent dietary compliance [2].

Children tend to heal faster than adults, with most achieving mucosal normalization within 1-2 years. Adults over 50 at the time of diagnosis have slower intestinal recovery and may take longer to achieve full histological normalization.

Nutritional Rehabilitation

Correcting deficiencies caused by years of malabsorption is as much a part of celiac treatment as eliminating gluten. At diagnosis, nutrient levels that should be measured include iron (ferritin and serum iron), B12, folate, vitamin D, calcium, zinc, magnesium, and selenium. Many patients are also thiamine-deficient.

Supplementation should be guided by blood work rather than blanket supplementation, since some nutrients can cause harm in excess. A few specific notes:

• Iron: Oral iron is often poorly tolerated in GI conditions. Ferrous bisglycinate (a chelated form) has better tolerability than ferrous sulfate. Intravenous iron infusion may be warranted in patients with severe deficiency or poor GI tolerance.
• Vitamin D: Deficiency is nearly universal at diagnosis. Therapeutic doses (typically 2,000-5,000 IU daily, adjusted by blood levels) are needed initially, not just maintenance doses.
• B12: Severely deficient patients may need intramuscular injections to bypass the still-impaired intestine, rather than relying on oral absorption.
• Zinc: Often depleted and important for intestinal epithelial repair. Zinc is a cofactor in hundreds of enzymatic reactions including DNA repair and immune function.

Bone health requires specific attention. Calcium (1,000-1,500 mg/day through diet and supplementation) alongside adequate vitamin D is essential to support bone mineral density recovery. DEXA scanning at diagnosis and repeat testing at 1-2 years allows tracking of bone density improvement.

Managing Persistent or Worsening Symptoms: Non-Responsive Celiac Disease

Approximately 20% of celiac patients continue to have symptoms despite adopting a gluten-free diet. Before assuming treatment failure or a more serious complication, a systematic evaluation is warranted [3]:

Step 1: Rule Out Continued Gluten Exposure

The most common cause of non-response is ongoing inadvertent gluten ingestion. A detailed dietary review with an experienced celiac dietitian, combined with testing of serum tTG-IgA (which should be falling over time), is the first step. Stool or urine gluten immunogenic peptide testing is available in some centers and can detect recent gluten exposure more sensitively than serology alone.

Step 2: Evaluate for Co-Existing Conditions

Several conditions commonly co-exist with celiac disease and can produce ongoing symptoms even after the intestine has healed:

• SIBO (small intestinal bacterial overgrowth): Villous atrophy and altered motility create conditions for bacterial overgrowth, which causes bloating, diarrhea, and malabsorption. Hydrogen breath testing can confirm diagnosis.
• Microscopic colitis: An inflammatory condition of the colon not visible on standard colonoscopy but diagnosed on biopsy. Associated with celiac disease and causes chronic watery diarrhea.
• Pancreatic exocrine insufficiency: Reduced pancreatic enzyme output from chronic intestinal damage; causes steatorrhea and bloating even on a gluten-free diet.
• IBS: Functional bowel symptoms can coexist independently of active celiac disease.
• Lactose intolerance: Damaged intestinal villi produce less lactase; many patients need to restrict dairy temporarily while the gut heals, even if they tolerated dairy before diagnosis.
• Food sensitivities: Some patients have genuine responses to FODMAPs, fructose, or other dietary components that persist even after gluten elimination.

Refractory Celiac Disease

Refractory celiac disease (RCD) is defined as persistent or recurrent malabsorptive symptoms and villous atrophy despite strict gluten-free diet adherence for at least 12 months, after all other causes have been excluded. It affects roughly 1-2% of celiac patients and is more common in those diagnosed after age 50 [4].

RCD is classified into two types based on the immunophenotype of the intraepithelial lymphocytes (IELs) lining the intestine:

• RCD Type I: IELs have a normal immunophenotype. Treated with corticosteroids (budesonide is preferred for its local intestinal effect with minimal systemic absorption) and, in some cases, immunosuppressants like azathioprine or steroids. Prognosis is generally better.
• RCD Type II: IELs have an aberrant immunophenotype (clonal expansion of IEL precursors). This is a premalignant condition with a 50-80% risk of progressing to enteropathy-associated T-cell lymphoma (EATL), an aggressive and often fatal malignancy. Management requires specialist involvement and may include cladribine, autologous stem cell transplantation, or enrollment in clinical trials [5].

Pharmacological Treatments in Development

Considerable pharmaceutical research is targeting celiac disease, driven by the limitations of the gluten-free diet (social burden, risk of cross-contamination, incomplete mucosal healing). Several promising approaches are in clinical trials:

Gluten-Degrading Enzymes

These are enzymes taken with meals to break down gluten before it can trigger an immune response. The peptides in gluten that activate the immune system are resistant to digestion by normal human enzymes; engineered proteases can cleave them. One agent, larazotide acetate, has advanced through Phase 2 trials [6]. Others, including IMGX003 (a combination of two prolyl endopeptidases), have shown reduction in gut permeability markers. These agents are not intended as a replacement for the gluten-free diet but as protection against inadvertent exposure, which is essentially unavoidable in the real world.

Tight Junction Modulators

Larazotide acetate works by tightening the junctions between intestinal epithelial cells (tight junctions), reducing the permeability that allows gluten peptides to cross the intestinal barrier and trigger immune activation. Phase 2b trials showed significant symptom reduction in patients with non-responsive celiac disease and high adherence to the gluten-free diet [7]. Phase 3 trials have faced mixed results, but the approach remains scientifically compelling.

Transglutaminase 2 Inhibitors

Tissue transglutaminase 2 (tTG2) is the enzyme that modifies gluten peptides, making them more immunogenic. Inhibiting tTG2 could theoretically prevent the immune activation cascade. Several small-molecule tTG2 inhibitors have entered early-phase trials.

HLA-Blocking Agents and Vaccines

Because celiac disease is strongly linked to specific HLA haplotypes (HLA-DQ2 and HLA-DQ8), which present modified gluten peptides to T cells, blocking these HLA molecules or tolerizing the immune system to gluten are both being explored. Nexvax2, a therapeutic peptide vaccine designed to induce tolerance, was studied in clinical trials. While those trials were discontinued, the approach of tolerization therapy is still considered scientifically viable.

IL-15 Antagonists

Interleukin-15 plays a central role in the pathogenesis of refractory celiac disease type II and in normal celiac disease. Anti-IL-15 agents are in early trials for RCD Type II. AMG 714, a human anti-IL-15 monoclonal antibody, showed some benefit in reducing IEL numbers in Phase 2 trials [8].

Regenerative Medicine Approaches to Gut Healing

Beyond symptom management and pharmaceutical targets, regenerative medicine offers a framework for thinking about accelerating intestinal repair after years of immune-mediated damage.

BPC-157 and Intestinal Mucosal Healing

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protein found in gastric juice. It has demonstrated robust intestinal healing properties in animal models, including acceleration of anastomosis healing, protection against NSAID-induced gut damage, and promotion of angiogenesis in intestinal tissue [9]. While human clinical trials specifically in celiac disease are lacking, BPC-157’s pro-healing effects on intestinal mucosa are physiologically relevant to celiac recovery. It is available compounded through clinical practices focusing on regenerative medicine.

NAD+ and Mitochondrial Support

Intestinal epithelial cells (enterocytes) have among the highest turnover rates in the body, regenerating every 2-5 days. This rapid regeneration is energetically demanding. NAD+ (nicotinamide adenine dinucleotide) is a central coenzyme in mitochondrial energy production, and NAD+ levels decline under conditions of chronic inflammation and oxidative stress. Supporting NAD+ levels through precursors like NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) may support the metabolic demands of intestinal healing, though clinical evidence in celiac disease specifically is preliminary [10].

Stem Cell Research

Experimental work on intestinal organoids (miniaturized gut tissue grown from intestinal stem cells) has produced new insights into celiac disease pathogenesis and is being explored as a platform for testing therapies. Broader stem cell approaches to gut repair are in early-stage research, not yet clinically available for celiac disease, but represent a longer-term direction in regenerative gastroenterology.

Gut Microbiome Restoration

The gut microbiome is profoundly altered in celiac disease, even after dietary treatment. Dysbiosis may perpetuate intestinal permeability and low-grade inflammation independently of gluten exposure [11]. Probiotic supplementation, particularly with Lactobacillus and Bifidobacterium strains that have demonstrated effects on intestinal barrier function, and fecal microbiota transplantation (FMT) as an investigational approach, are active areas of research in celiac disease management.

Monitoring After Diagnosis

Celiac disease requires ongoing monitoring, not just treatment. Recommended follow-up includes:

• Repeat tTG-IgA at 6 months and 12 months post-diagnosis to confirm antibody normalization
• Repeat small bowel biopsy at 1-2 years for adults (to confirm mucosal healing, particularly in those with persistent symptoms)
• Annual blood work: complete blood count, iron studies, B12, folate, vitamin D, zinc
• DEXA scan at diagnosis and repeated at intervals based on initial findings
• Thyroid function testing at diagnosis (autoimmune thyroid disease is significantly more common in celiac disease)
• Monitoring for associated autoimmune conditions: type 1 diabetes, autoimmune hepatitis, Sjogren’s syndrome

Related Reading

• Celiac Disease Symptoms: Beyond Digestive Issues
• Celiac Disease Diet: The Complete Guide to Going Gluten-Free
• Non-Celiac Gluten Sensitivity: What It Is and How It Differs from Celiac
• Leaky Gut Symptoms: Separating Fact From Fiction
• BPC-157 Dosage and Administration Guide

References

1. Catassi C, Fabiani E, Iacono G, et al. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85(1):160-166. doi:10.1093/ajcn/85.1.160. PMID: 17209192
2. Rubio-Tapia A, Rahim MW, See JA, et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol. 2010;105(6):1412-1420. doi:10.1038/ajg.2010.10. PMID: 20145607
3. Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D, Kelly CP. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol. 2007;5(4):445-450. doi:10.1016/j.cgh.2006.12.006. PMID: 17382600
4. Malamut G, Cellier C. Refractory celiac disease. Curr Opin Oncol. 2013;25(5):445-451. doi:10.1097/CCO.0b013e3283644c7d. PMID: 23857366
5. Rubio-Tapia A, Murray JA. Classification and management of refractory coeliac disease. Gut. 2010;59(4):547-557. doi:10.1136/gut.2009.195131. PMID: 20332526
6. Tye-Din JA, Anderson RP. Immunopathogenesis of celiac disease. Curr Gastroenterol Rep. 2008;10(5):458-465. doi:10.1007/s11894-008-0084-8. PMID: 18799117
7. Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107(10):1554-1562. doi:10.1038/ajg.2012.211. PMID: 22850429
8. Cellier C, Bouma G, van Gils T, et al. Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Gastroenterol Hepatol. 2019;4(12):960-970. doi:10.1016/S2468-1253(19)30265-1. PMID: 31563499
9. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. doi:10.2174/13816128113199990421. PMID: 23782145
10. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018;27(3):529-547. doi:10.1016/j.cmet.2018.02.011. PMID: 29514064
11. Caminero A, Verdu EF. The role of the microbiome in celiac disease pathogenesis. Gastroenterol Clin North Am. 2019;48(1):173-186. doi:10.1016/j.gtc.2018.09.013. PMID: 30711216